cost-effectiveness of three echinocandins and fluconazole in the treatment of candidemia and/or invasive candidiasis in nonneutropenic adult patients
Clicks: 256
ID: 225681
2015
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
256 views
40 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #34 of 51 articles by views in TheScientificWorldJournal
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
S Grau,1 JC Pozo,2 E Romá,2 M Salavert,3 JA Barrueta,4 C Peral,4 I Rodriguez,5 D Rubio-Rodríguez,6 C Rubio-Terrés6 1Hospital del Mar (IMIM), Barcelona, 2Hospital Universitario Reina Sofía, Córdoba, 3Hospital Universitario y Politécnico La Fe, Valencia, 4Pfizer SLU, Alcobendas, 5Trial Form Support, Madrid, 6Health Value, Madrid, Spain Objective: To estimate the cost-effectiveness of three echinocandins (anidulafungin, caspofungin, and micafungin) and generic fluconazole in the treatment of nonneutropenic adult patients with candidemia and/or invasive candidiasis in intensive care units in Spain. Materials and methods: A decision-tree model was applied. The success and safety (hepatic and renal adverse effects) of first-line treatments were obtained from meta-analyses and systematic reviews of clinical trials. In the case of failure, a second-line treatment (liposomal amphotericin B after the echinocandins, or one of the echinocandins after fluconazole) was administered. The duration of the treatments (14 days total) was established by a panel of clinical experts using the Delphi method and according to Infectious Diseases Society of America guidelines. The cost of the medications and renal toxicity were considered. Deterministic and probabilistic sensitivity analysis using Monte Carlo simulations were carried out. Results: The total cost of the treatment of candidemia and/or invasive candidiasis with anidulafungin, caspofungin, micafungin, and fluconazole was €5,483, €5,968, €6,231, and €2,088, respectively. Anidulafungin was the dominant treatment (more effective, less expensive) compared to micafungin and caspofungin. The cost of achieving one more patient successfully treated with anidulafungin, caspofungin, and micafungin compared to fluconazole was €17,199, €23,962, and €27,339, respectively. The result remained stable, despite modification of the duration of the first-line and second-line treatments, as well as most of the dosing regimens. The probabilistic analysis also remained stable. Conclusion: In accordance with this economic study, anidulafungin would produce savings and would be the dominant treatment compared with micafungin and caspofungin in nonneutropenic adult patients with candidemia and/or invasive candidiasis in intensive care units in Spain. Keywords: invasive candidiasis, candidemia, anidulafungin, micafungin, caspofungin, fluconazole, cost-effectiveness analysis
| Reference Key |
s2015clinicoeconomicscost-effectiveness
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Grau S;Pozo JC;Romá E;Salavert M;Barrueta JA;Peral C;Rodriguez I;Rubio-Rodríguez D;Rubio-Terrés C |
| Journal | TheScientificWorldJournal |
| Year | 2015 |
| DOI |
DOI not found
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.